Compare ESCA & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESCA | AKBA |
|---|---|---|
| Founded | 1922 | 2007 |
| Country | United States | United States |
| Employees | N/A | 194 |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.2M | 248.3M |
| IPO Year | 1995 | 2014 |
| Metric | ESCA | AKBA |
|---|---|---|
| Price | $19.51 | $0.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | 21.0K | ★ 7.2M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.50% | N/A |
| EPS Growth | 6.45 | ★ 93.94 |
| EPS | ★ 1.00 | N/A |
| Revenue | ★ $180,541,000.00 | N/A |
| Revenue This Year | $4.15 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.52 | ★ N/A |
| Revenue Growth | ★ 2.71 | N/A |
| 52 Week Low | $11.41 | $0.81 |
| 52 Week High | $23.07 | $3.19 |
| Indicator | ESCA | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 44.64 | 40.80 |
| Support Level | $19.35 | $0.85 |
| Resistance Level | $21.23 | $0.96 |
| Average True Range (ATR) | 0.48 | 0.05 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 36.81 | 4.08 |
Escalade Inc manufactures and distributes sporting goods for a varied range of activities. These sports include archery, table tennis, basketball goals, trampoline, play systems, fitness, game tables like hockey and soccer, billiards, darting, and other outdoor games. These products are sold under the brand names like Goalrilla, Goalsetter, Woodplay, Silverback, Nodor, Rage, Child Life, among others. The geographic segments in which the company operates are the United States, Canada, Australia, and Other regions.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.